Semaglutide Dosing Protocols in Clinical Studies
Semaglutide is an FDA-approved prescription compound. The following describes the dose titration schedules studied in clinical trials and reflected in FDA-approved labeling — not a personal dosing recommendation.
STEP trial protocol (subcutaneous, weight management): A five-step titration minimizing GI intolerability:
| Weeks | Dose (subcutaneous) | Frequency |
|---|---|---|
| 1–4 | 0.25 mg | Once weekly |
| 5–8 | 0.5 mg | Once weekly |
| 9–12 | 1.0 mg | Once weekly |
| 13–16 | 1.7 mg | Once weekly |
| 17+ | 2.4 mg (maintenance) | Once weekly |
This titration produced the 14.9% mean weight reduction at 68 weeks in STEP 1.[1] The slow escalation was specifically designed to minimize the dose-dependent GI adverse effects documented across the trial program.
SUSTAIN programme (subcutaneous, type 2 diabetes): Diabetes-indication doses of 0.5 mg and 1.0 mg subcutaneous once weekly, studied in SUSTAIN 1–6. HbA1c reductions of approximately 1.5 percentage points documented at both doses.
PIONEER programme (oral, type 2 diabetes): Three-step oral titration: 3 mg once daily (weeks 1–4), 7 mg once daily (weeks 5–8), 14 mg once daily maintenance (week 9+). HbA1c reductions of 1.0–1.4 percentage points at the 14 mg maintenance dose at 26 weeks.[9]
Administration requirement for oral formulation: tablet taken fasting with up to 120 mL of water; 30-minute waiting period before eating, drinking (other than water), or other oral medications — required for adequate gastric absorption via the SNAC enhancement mechanism.[10]
Semaglutide Half-Life and Pharmacokinetics
Semaglutide elimination half-life: approximately 145–168 hours for both subcutaneous and oral formulations, enabling once-weekly subcutaneous dosing.[10] This compares to a half-life of approximately 2 minutes for native GLP-1 — the structural modifications (DPP-4-resistant Aib8 substitution, albumin-binding C18 fatty diacid chain) account for the 4,000-fold extension.[12]
Steady-state plasma concentrations are reached after 4–5 weeks of continuous once-weekly administration per pharmacokinetic modeling in Phase 1 studies.[10] Oral bioavailability is approximately 0.8% — low, but sufficient given the larger milligram doses delivered orally versus subcutaneously.
Metabolism: via proteolytic cleavage and beta-oxidation; excreted renally and fecally. No major active metabolites identified in Phase 1 characterization.
Drug interactions: a dedicated pharmacokinetic study showed semaglutide had no clinically relevant effects on the total exposure (AUC) of metformin, warfarin, or digoxin despite its gastroparesis effect. Atorvastatin peak concentration (Cmax) was reduced approximately 38% by delayed gastric emptying, but total AUC was unchanged; no dose adjustment required.[11]
How long does Semaglutide stay in your system?
The elimination half-life of semaglutide is approximately 1 week (145–168 hours), enabling once-weekly dosing; steady-state plasma concentrations are reached after 4–5 weeks of continuous weekly administration per pharmacokinetic modeling in Phase 1 studies.[10]
Discontinuation findings in Semaglutide trials
Weight regain following discontinuation is well-documented. STEP 1 trial extension: approximately 11.6 percentage points weight regain within one year of discontinuing semaglutide; net body weight loss versus baseline was 5.6% at week 120, compared to 17.3% at week 68.[3]
STEP 4 (withdrawal design): participants who continued semaglutide after a 20-week run-in lost an additional 7.9% at 48 weeks; those switched to placebo regained 6.9% of body weight. Net treatment difference at 68 weeks: 14.8 percentage points favoring continued semaglutide.[4]
GI symptoms (nausea, diarrhea, constipation) generally resolve within weeks of discontinuation per clinical observation data. No physiological withdrawal syndrome has been identified in trial data. Cardiometabolic biomarker improvements documented in STEP exploratory analyses — blood pressure, lipid improvements — also reversed on discontinuation.[8]
Can you stop Semaglutide cold turkey?
STEP 4 withdrawal extension showed approximately 11.6% weight regain within 1 year of discontinuation, with GI symptoms generally resolving within weeks — no physiological withdrawal syndrome has been identified in trial data.[3] [4]
What are the proper doses for Semaglutide?
STEP and SUSTAIN trial protocols used a 4-to-5-step titration: beginning at 0.25 mg/week, escalating to 2.4 mg/week maintenance over 16 weeks — designed to minimize GI intolerability during escalation. PIONEER oral protocols begin at 3 mg/day, reaching 14 mg/day maintenance over 8 weeks.[1] [9] These are FDA-labeled doses studied in clinical trials, not individual dosing recommendations.